New Delhi: Drug firm Dr Reddy’s Laboratories today announced the launch of Finrid, a drug used in the treatment of chronic pain, in India.
“Being a controlled substance, Finrid will be sold through an independent distribution structure and will be available across hospitals and palliative care centres in India,” Dr Reddy’s said in a statement.
Controlled substances are produced using narcotic substances and are sold through special channels.
The product is licensed from Sparsha pharma and is the first opiod (derived from Opium) transdermal patch to be developed in India, it added.
Finrid is available in transdermal patch form, which means it is administered through skin in patients suffering from chronic pain because of diseases such as cancer, rheumatoid arthritis and other problems.
The drug is administered through an adhesive patch that is placed on the skin to deliver a specific amount of drug into the blood stream.